Sugi Predict

Sugi Predict / Compounds / SCHEMBL150081

SCHEMBL150081

SCHEMBL150081

Cc1cccc(N2CCNC2=O)c1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 3/20 0.60
▸ MEN1 O00255 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ ADRB1 P08588 1/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ HSP90AA1 P07900 1/20 0.47
▸ MGLL Q99685 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ HSD11B1 P28845 3/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21637754 0.90 ALOX5 (0.54) ALOX5MEN1POLBKMT2AADRB1
SCHEMBL22562807 0.89 ALOX5 (0.52) ALOX5MEN1POLBKMT2AADRB1
SCHEMBL23601594 0.83 PARP10 (0.48) ALOX5MEN1POLBKMT2AADRB1
SCHEMBL10704865 0.81 ADRB1 (0.51) ALOX5MEN1POLBKMT2AADRB1
SCHEMBL5056229 0.81 ALOX5 (0.50) ALOX5MEN1POLBKMT2AL3MBTL1
SCHEMBL7344849 0.81 ALOX5 (0.59) ALOX5MEN1KMT2AADRB1MGLL
SCHEMBL1965858 0.81 DDB1 (0.61) ALOX5MEN1KMT2AADRB1MAPT
SCHEMBL5604528 0.80 ADRB1 (0.55) ALOX5ADRB1MGLLMAPTDRD2
SCHEMBL1787047 0.79 ALDH1A1 (0.51) ALOX5MEN1KMT2AL3MBTL1MGLL
SCHEMBL5182221 0.79 FAAH (0.47) ALOX5MEN1POLBKMT2AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023022497-A1 SOS1 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-02-23 — — WO disclosed
US-9339501-B2 17a-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2016-05-17 — — US disclosed
US-20150209356-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2015-07-30 — — US disclosed
US-9029399-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-05-12 — — US disclosed
US-RE45173-E1 Inhibitors of CYP 17 NOVARTIS AG (CH) 2014-09-30 — — US disclosed
US-20140228386-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-08-14 — — US disclosed
US-20140228394-A1 INHIBITORS OF CYP 17 NOVARTIS AG (CH) 2014-08-14 — — US disclosed
CN-102803250-B 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 NOVARTIS AG 2014-04-16 — — CN disclosed
EP-2445903-B1 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 NOVARTIS AG (CH) 2014-03-26 — — EP disclosed
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 — — EP disclosed
US-20080280919-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS GLAXO GROUP LIMITED 2008-11-13 — — US disclosed
EP-1876174-A1 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors GLAXO GROUP LIMITED (GB) 2008-01-09 — — EP disclosed
US-7279481-B2 Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors GLAXO GROUP LIMITED (GB) 2007-10-09 — — US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 — — WO disclosed
US-20070167423-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS GLAXO GROUP LIMITED 2007-07-19 — — US disclosed
US-20060229312-A1 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors GLAXO GROUP LIMITED (GB) 2006-10-12 — — US disclosed
EP-1646613-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS GLAXO GROUP LIMITED (GB) 2006-04-19 — — EP disclosed
WO-2005014552-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS GLAXO GROUP LIMITED (GB) 2005-02-17 — — WO disclosed
US-4642351-A TREATMENT OF OXAZOLIDINONE WITH ISOCYANATE OR ISOTHIOCYANATE THE DOW CHEMICAL COMPANY (US) 1987-02-10 — — US disclosed
US-3988345-A HYPOTENSIVE AGENTS; PHOSPHORUS OXYCHLORIDE CHEMIE LINZ AKTIENGESELLSCHAFT (OE) 1976-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228394-A1 INHIBITORS OF CYP 17 CYP17A1, CYP21A2, CYP4A22 ALOX5 559/4885MEN1 2911/4885POLB 1277/4885
US-20150209356-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 ALOX5 1069/4885MEN1 1136/4885POLB 1707/4885
US-20140228386-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 ALOX5 1069/4885MEN1 1136/4885POLB 1707/4885
US-20080280919-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS HTR1A, HTR1D, HTR1F ALOX5 3296/4885MEN1 915/4885POLB 2306/4885
US-20070167423-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS HTR1A, HTR1D, HTR1F ALOX5 3556/4885MEN1 692/4885POLB 3053/4885
US-20060229312-A1 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors HTR1A, HTR1D, HTR1F ALOX5 3556/4885MEN1 692/4885POLB 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback